Jiayan Ma
Impact in
- Health Information Management top 10%
- Artificial Intelligence in Healthcare
Papers in
-
- MicroRNA in disease regulation 1
-
- COVID-19 Clinical Research Studies 2
- Co-authors
- Mahadevan Raj Rajasekaran (3 shared papers)Eric Yao Chang (3 shared papers)Weg M. Ongkeko (4 shared papers)Wei Tse Li (4 shared papers)Aditi Gnanasekar (3 shared papers)Qi Xie (2 shared papers)Min Tang (2 shared papers)Martin Haas (1 shared paper)
- Journals
- Computational and Structural Biotechnology Journal (2 papers)Journal of Clinical Laboratory Analysis (1 paper)Nucleic Acids Research (1 paper)BMC Cancer (1 paper)Clinical & Translational Oncology (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Jiayan Ma
9 papers receiving 461 citations
Peers
Comparison fields: 5 of 72
- Health Informatics 13
- Health Information Management 37
- Biotechnology 26
- Molecular Biology 213
- Radiology, Nuclear Medicine and Imaging 72
Countries citing papers authored by Jiayan Ma
This map shows the geographic impact of Jiayan Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiayan Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiayan Ma more than expected).
Fields of papers citing papers by Jiayan Ma
This network shows the impact of papers produced by Jiayan Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiayan Ma. The network helps show where Jiayan Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Jiayan Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 139 | |
| 2 | 2021 | 107 | |
| 3 | 2020 | 90 | |
| 4 | 2022 | 73 | |
| 5 | 2018 | 20 | |
| 6 | 2022 | 14 | |
| 7 | 2020 | 12 | |
| 8 | 2021 | 12 | |
| 9 | 2021 | 3 | |
| 10 | 2025 | 1 | |
| 11 | 2026 | 0 |
About Jiayan Ma
Jiayan Ma is a scholar working on Cancer Research, Infectious Diseases, Oncology, Biotechnology and Molecular Biology, having authored 11 papers that have together received 471 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (2 papers), Cancer Immunotherapy and Biomarkers (1 paper), Sepsis Diagnosis and Treatment (1 paper), Pancreatic and Hepatic Oncology Research (1 paper), Autophagy in Disease and Therapy (1 paper), MicroRNA in disease regulation (1 paper), Single-cell and spatial transcriptomics (1 paper) and Prostate Cancer Treatment and Research (1 paper). The work is most often cited by research in Health Informatics (13 citations), Health Information Management (37 citations), Biotechnology (26 citations), Molecular Biology (213 citations) and Radiology, Nuclear Medicine and Imaging (72 citations). Jiayan Ma has collaborated with scholars based in China and United States. Frequent co-authors include Mahadevan Raj Rajasekaran, Eric Yao Chang, Weg M. Ongkeko, Wei Tse Li, Aditi Gnanasekar, Qi Xie, Min Tang, Martin Haas, Jessica Wang‐Rodriguez and Joseph C. Tsai. Their work appears in journals such as Computational and Structural Biotechnology Journal, Journal of Clinical Laboratory Analysis, Nucleic Acids Research, BMC Cancer and Clinical & Translational Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.